Pfizer, in New York, and his German wife said that exploratory talks with the European Commission, the bloc’s executive arm, had been a success and that contract negotiations would now begin.
Under the terms proposed in the agreement, 200 million doses of the BNT162 research candidate vaccine will be delivered to EU member states, with the option of another hundred million doses.
However, any agreement, which would constitute the largest initial request for vaccines to date, is subject to clinical good luck and regulatory approval.
Albert Bourla, president and CEO of Pfizer, said: “We have activated our chain of origin, especially our site in Belgium, and we are starting to manufacture to make our vaccine available as soon as possible, if our clinical trials are successful. regulatory approval is granted. “
Candidate BNT162, who is acting against Sars-CoV-2, the culprit covid-19 virus, is recently in Phase 2/3 of the US Food and Drug Administration’s rapid follow-up studies. But it’s not the first time The first step towards approval can only be requested from October 2020. The Phase 2/3 exam involved up to 30,000 participants between the ages of 18 and 85.
In July, the U. S. government will be able to do so. But it’s not the first time It showed that it would spend $1. 95 billion to get the first hundred million doses of the possible vaccine.
Pfizer and BioNTech plan to deliver up to one hundred million doses by the end of 2020 and approximately 1. 3 million by the end of 2021, assuming good luck and approval of the vaccine.
Pfizer shares rose 1% before trading after the announcement, while Nasdaq-listed BioNTech rose nearly 6%.
The price of investments can move up and down, so you may invest less than you invest. It is therefore vital that you perceive the dangers and commitments. This online page is not a personalized recommendation based on your situation. informed decisions for you, our goal is to provide you with the most productive information, the most productive service and the most productive prices. If you are unsure of the suitability of an investment, please contact us for a recommendation.